Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 515 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Target Lesion Clear all
Completed Not applicable Interventional Results available

The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance

NCT02509065
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Bionic Pancreas, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 25, 2026, 4:08 PM EDT
Completed No phase listed Observational

Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy

NCT00508703
View directory record Official record
Conditions
Uterine Cancer, Cervical Cancer, Endometrial Cancer
Interventions
Intensity Modulated Radiotherapy (IMRT), CT Scan
Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 25, 2026, 4:08 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Glutamatergic Mechanisms: Aim2

NCT05401227
View directory record Official record
Conditions
Healthy
Interventions
Ketamine, Ts-134 or XT, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 25, 2026, 4:08 PM EDT
Completed Not applicable Interventional Results available

Cognitive Enhancement as a Target for Cocaine Pharmacotherapy

NCT01531153
View directory record Official record
Conditions
Addiction
Interventions
Galantamine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 25, 2026, 4:08 PM EDT
Completed Not applicable Interventional

Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer

NCT02132845
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
cytology specimen collection procedure, targeted therapy, therapeutic procedure, laboratory biomarker analysis
Other · Drug · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 25, 2026, 4:08 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

NCT03533257
View directory record Official record
Conditions
Alzheimer Disease
Interventions
AMX0035, Placebo
Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 89 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Jacksonville, Florida • Orlando, Florida • Palmetto Bay, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 25, 2026, 4:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

NCT02414269
View directory record Official record
Conditions
Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer, Breast Cancer
Interventions
iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab
Genetic · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 4:08 PM EDT
Not yet recruiting Not applicable Interventional

Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors

NCT07793994
View directory record Official record
Conditions
CNS Tumor, Solid Tumor, Relapsed Cancer, Refractory Cancer, Pediatric Cancer
Interventions
Bulk RNA Sequencing, Immunohistochemistry (IHC)
Diagnostic Test
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 30 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 25, 2026, 4:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Task Switching Behavior Between Target Templates During Visual Search in Healthy Adults

NCT05786651
View directory record Official record
Conditions
Healthy
Interventions
Experimental: Within-Subjects Attentional Information
Behavioral
Lead sponsor
Lehigh University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 25, 2026, 4:08 PM EDT
Completed Phase 3 Interventional

Strategies to Maintain Cardiac Risk Control After Discharge From Cardiovascular Risk Reduction Clinic

NCT00358033
View directory record Official record
Conditions
Diabetes, Dyslipidemia, Hypertension, Coronary Atherosclerosis
Interventions
Counseling, Interactive Education, Group Support, Pharmacologic case management
Behavioral · Procedure
Lead sponsor
Providence VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 25, 2026, 4:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

NCT01582880
View directory record Official record
Conditions
Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Systemic, Rheumatoid Arthritis, Other Autoimmune Diseases
Interventions
Riboflavin
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 25, 2026, 4:08 PM EDT
Active, not recruiting Not applicable Interventional

DBS of the Lateral Habenula in Treatment-Resistant Depression

NCT01798407
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
Activa Tremor Control Sys (DBS Implant), Randomized, staggered withdrawal phase
Device · Other
Lead sponsor
Wayne Goodman MD
Other
Eligibility
21 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 25, 2026, 4:08 PM EDT
Completed Not applicable Interventional Results available

HEARTS R34 Feasibility Study, Autistic Participants

NCT05608083
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
HEARTS classes, Online discussion group
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 25, 2026, 4:08 PM EDT
Active, not recruiting Phase 1 Interventional

Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder

NCT05223829
View directory record Official record
Conditions
PTSD, Alcohol Use Disorder
Interventions
Brexanolone
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 25, 2026, 4:08 PM EDT
Terminated Not applicable Interventional

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

NCT04313725
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions
Tangible Boost, Placebo
Device · Other
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 25, 2026, 4:08 PM EDT
Terminated Phase 2Phase 3 Interventional

Lamictal in the Treatment of Post-Herpetic Neuralgia

NCT00295776
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
Lamictal in the treatment of Post-Herpetic Neuralgia
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 85 Years
Timeline
Started 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 25, 2026, 4:08 PM EDT
Completed Phase 3 Interventional

Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor

NCT00047125
View directory record Official record
Conditions
Carcinoma of Unknown Primary
Interventions
radiation therapy
Radiation
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
237
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 180 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 25, 2026, 4:08 PM EDT
Completed No phase listed Observational

Collection of Tissue Samples for Study of Multidrug Resistance

NCT00880503
View directory record Official record
Conditions
Breast Carcinoma, Breast Cancer, Medullary Thyroid Carcinoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 25, 2026, 4:08 PM EDT
Active, not recruiting Phase 2 Interventional Results available

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

NCT04214249
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Hematopoietic Cell Transplantation, Idarubicin Hydrochloride, Multigated Acquisition Scan, Pembrolizumab, Punch Biopsy
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 25, 2026, 4:08 PM EDT
Recruiting Not applicable Interventional

Sleep Mechanisms Of Regulating Emotions

NCT06373718
View directory record Official record
Conditions
Insomnia, Depression
Interventions
Cognitive Behavioral Therapy for Insomnia
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 25, 2026, 4:08 PM EDT
Completed Not applicable Interventional Results available

Cognitive Dysfunction in Parkinson's Disease

NCT02346708
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Real TMS, Sham TMS
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 25, 2026, 4:08 PM EDT
Completed Not applicable Interventional

Novel Behavioral Intervention to Enhance Social Connections in Anxiety and Depression

NCT03196544
View directory record Official record
Conditions
Anxiety Disorders and Symptoms, Depression
Interventions
Social Approach Training (5 sessions), Social Approach Training (10 sessions)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 25, 2026, 4:08 PM EDT
Terminated Early Phase 1 Interventional

Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer.

NCT00364364
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Radiolabeled humanized PAM4 IgG
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 25, 2026, 4:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Autism Oxytocin Brain Project

NCT03033784
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
8 International Units (IU) of Oxytocin, 24IU of Oxytocin, 48IU of Oxytocin, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 25, 2026, 4:08 PM EDT